News 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, November 21, 2018 /PRNewswire/ — OBI Pharma, …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan. September 18, 2018 /PRNewswire/ — OBI …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
First Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, July 9, 2018 /PRNewswire/ — OBI Pharma, Inc., …
OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors
First clinical trial to test the safety and efficacy of a novel first-in-class targeted therapy (small-molecule prodrug) that selectively releases a potent DNA alkylating agent for solid tumors that express …
OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)
First Clinical Trial to Test the Safety and Preliminary Activity of Passive Immunotherapy based on a Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. Taipei, …